tbuckley/cabot-search huggingface dataset:
Determinants and Impact of Treatment Interruptions and Nonadherence to Imatinib Therapy in Patients with Chronic Myeloid Leukemia in a South Brazilian Cohort
Authors: Marcelo Capra, Laura Fogliatto, Mariza Shaan, Mayde Seadi Torriani, Tito Vanelli Costa, Mario Sérgio Fernandes, Katia Fassina, Denise Almeida, Marco Antônio Schilling, Tânia Hellwig, Virgínia Coser, Dalnei Veiga Pereira, Waldir Veiga Pereira, Mariangela Moschen, Tiago Daltoe, Sabrina Wisintainer, Cheila Eickhoff, Viviane Magagnin Fernandes, Juliana Kratochvil, Saozan Ahmad, Adriana Zardo, Andréia Dias Almeida, Vitor Lenz, Márcia Leite, Moema Nene, Dayane Koshiyama, Nathália Guterres Xavier, Liane Esteves Daudt, Lucia Silla
Journal: Blood (2011)
Allergen Sensitization Is Associated with Increased Rates of Exacerbations, Oral Corticosteroid (OCS) Use, and Asthma-Related Healthcare Services in Children with Severe or Poorly Controlled Asthma
Authors: W. Gerald Teague, Evgeniya Antonova, Amanda M. Kong, Yao Ding, Ahmar Iqbal, Bradley W. Chipps
Journal: Journal of Allergy and Clinical Immunology (2017)
311P Blockade of vascular endothelial growth factor receptors by tivozanib inhibits growth and restores chemosensitivity in human ovarian carcinoma cells
Authors: G. Zarrinrad, M. Momeny, Z. Sabourinejad, F. Moghaddaskho, H. Eyvani, H. Yousefi, A. Poursheikhani, F. Barghi, F. Esmaeilii, M. Yaghmaiee, K. Alimoghaddam, A. Ghavamzadeh, S. Ghaffari
Journal: Annals of Oncology (2016)
The Presence of An Internal Tandem Duplicate of FlT3 Receptor (ITD) Is An Unfavorable Prognostic Factor on the Outcome of Adult Patients with Acute Myeloid Leukemia (AML) Autografted in First Remission (CR1) Only in the Absence of An NPM1 Mutation,
Authors: Norbert C. Gorin, Myriam Labopin, Giovanna Meloni, Arnaud Pigneux, Jordi Esteve, Miguel A. Sanz, Alberto Bosi, William Arcese, Giuseppe Milone, Emmanuelle Polge, Mohamad Mohty
Journal: Blood (2011)
275P Clinical outcomes of second transurethral resection in non-muscle invasive high grade bladder cancer: a retrospective, multi-institutional, collaborative study
Authors: N. Kamiya, H. Suzuki, T. Suyama, M. Kobayashi, S. Fukasawa, N. Sekita, K. Mikami, N. Nihei, Y. Naya, T. Ichikawa
Journal: Annals of Oncology (2016)
Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity
Authors: Matthew P Salzberg, Jocelyn C Maragulia, Oliver W. Press, Thomas M Habermann, Julie M Vose, Martin Bast, Ranjana H. Advani, Andrew M. Evens, Nahida Islam, John P. Leonard, Peter Martin, Peter J Hosein, Andrew D Zelenetz, Izidore S Lossos
Journal: Blood (2012)
Efficacy and Safety of Once-Daily, Oral Iron Chelator Deferasirox (Exjade®) in a Large Group of Regularly Transfused Patients with β-Thalassemia Major
Authors: Maria Domenica Cappellini, Mohsen Saleh Elalfy, Antonis Kattamis, John F Seymour, Chan Lee Lee, John B Porter, Amal El-Beshlawy, Dany Habr, Gabor Domokos, Abdel Hmissi, Ali Taher
Journal: Blood (2008)
Pentostatin and Cyclophosphamide with or without Rituximab Has Significant Activity in Patients with Previously Treated Chronic Lymphocytic Leukemia and Other Low Grade Lymphoid Neoplasms.
Authors: Nicole Lamanna, Matt Kalaycio, Peter Maslak, Joseph Jurcic, David A. Scheinberg, Alison N. Gencarelli, Denise Horgan, Mark A. Weiss
Journal: Blood (2004)
Preliminary Clinical, Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of the Safety Run-In Part of a Phase II Trial of Orally Available MEK-Inhibitor MSC1936369 in Patients (Pts) with Advanced Hematological Malignancies (HM)
Authors: Farhad Ravandi, Arnaud Pigneux, Daniel J. DeAngelo, Hervé Dombret, Jacques Delaunay, Xavier Thomas, Tapan Kadia, Christian Luepfert, Ekaterine Asatiani, Margarita Donica, Hagop M. Kantarjian, B. Douglas Smith
Journal: Blood (2011)
Bevacizumab in routine clinical practice for first-line therapy with platinum-based chemotherapy of patients with advanced adenocarcinoma of the lung in Germany
Authors: H.R. Wirtz, S. Lang, J. Mezger, S. Hammerschmidt, T. Gaska, C. Lerchenmueller, M. Reck, S. Haas, D. Reichert, G. Hoeffken
Journal: Annals of Oncology (2016)
Targeting the HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities in Alzheimer’s Disease
Authors: Dan Liu, Hui Tang, Xin-Yan Li, Man-Fei Deng, Na Wei, Xiong Wang, Ya-Fan Zhou, Ding-Qi Wang, Peng Fu, Jian-Zhi Wang, Sébastien S. Hébert, Jian-Guo Chen, Youming Lu, Ling-Qiang Zhu
Journal: Molecular Therapy (2017)
Modulation of Cell Surface Protein Free Thiols; A Potential Novel Mechanism of Action of the Sesquiterpene Lactone Parthenolide in Non-Hodgkin's Lymphoma.
Authors: Jolanta Skalska, Paul S Brookes, S. M Nadtochy, Shannon Hilchey, Craig T. Jordan, Monica L. Guzman, Sanjay Maggirwar, Margaret M Briehl, Steven H. Bernstein
Journal: Blood (2009)
Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM)
Authors: A.B. Lassman, M. van den Bent, H.K. Gan, D.A. Reardon, P. Kumthekar, N. Butowski, Z. Lwin, T. Mikkelsen, L.B. Nabors, K.P. Papadopoulos, M. Penas-Prado, J. Simes, H. Wheeler, E. Gomez, H.-J. Lee, L. Roberts-Rapp, H. Xiong, E. Bain, K. Holen, R. Merrell
Journal: Annals of Oncology (2016)
Annals Story Slam - I Am Not My Hair
Authors: Traci Trice
Journal: Annals of Internal Medicine (2017)

Web Exclusives7 February 2017Annals On Being a Doctor Story Slam - I Am Not My HairFREETraci Trice, MDTraci Trice, MDFrom Thomas Jefferson University Hospital, Philadelphia, PennsylvaniaSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0021 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - I Am Not My Hair "I Am Not My Hair," by Traci Trice, MD (Duration 5:51)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: From Thomas Jefferson University Hospital, Philadelphia, PennsylvaniaCurrent Author Address: Traci Trice, MD, Thomas Jefferson University Hospital, Philadelphia, PA; e-mail, Traci.[email protected]edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 February 2017Volume 166, Issue 3Page: SS1 ePublished: 7 February 2017 Issue Published: 7 February 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
National Cancer Institute Monograph 40, February 1974 “The National Cancer Program and International Cancer Research”
Authors: John R. Heller, Anthony M. Bruno
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article National Cancer Institute Monograph 40, February 1974 “The National Cancer Program and International Cancer Research” Get access JNCI: Journal of the National Cancer Institute, Volume 52, Issue 4, April 1974, Page 1387, https://doi.org/10.1093/jnci/52.4.1387-a Published: 01 April 1974
Provider-survivor communication: Identifying and addressing unmet needs.
Authors: Angela K. Patterson, Cam Escoffery, James Hotz, Nancy M. Paris, Donna L. Meyer, Joan M. Giblin, Katherine S. Michaud, Logan J Kirsch, Barbara J. Wilson, Jennifer Fournier, Carolyn Helmer, Catherine Comer, Joan Kines, Mary Ann Heddon, Tobyanne Sidman, Tamira M. Moon, Rachel Cannady
Journal: Journal of Clinical Oncology (2016)

81 Background: The Georgia Cancer Control Consortium’s Survivorship Working Group conducted a needs assessment to understand physical, psychological, practical, and spiritual needs of adult survivors. Results were used to assess survivors’ level of distress and how effectively their needs were being met. Methods: Cross-sectional online and paper-based surveys developed using NCCN and Commission on Cancer (CoC) guidelines. Surveys were distributed through survivorship programs of CoC hospitals (n = 40) and cancer organizations via email, social media and mail. 740 responses received September-December 2014. Results: Respondents were primarily female (78%) married (65%), college-educated (55%) and insured (97%). 83% were White,16% were African American and 3% were Hispanic. 36% of respondents were within 1 year of treatment; 45% were 1 - 5 years post treatment. Survivors reported positive experiences with provider communication. Responses of ‘often’ or ‘very often’ were: provider gave them a chance to ask questions (90.6%); provider involved them in healthcare decisions (84.7%), provider spent enough time with them (78.5%) and provider helped with feelings of uncertainty about health issues or treatment (75.7%). Physical and emotional needs were not as effectively met as spiritual or practical needs. A higher proportion of survivors reported moderate to extreme levels of emotional distress with: depression (32.7%), anxiety (32.1%), stress (30.2%), fear of recurrence (28.2%) and defining a “new normal” (25.9%). 81% of survivors found information and assistance online (56%), in print materials (41%) and from providers/cancer centers (41%). 37% received a survivorship care plan (SCP); 98% reported the SCP was helpful. Conclusions: Results demonstrate the need for providers in Georgia to be educated about and responsive to survivors’ unmet needs and levels of distress. Survivors report positive communication with providers but lower levels of having physical and emotional needs addressed. Survivors actively seek resources and benefit from SCPs. Providers can contribute to addressing needs and reducing distress by maintaining strong communication, guiding survivors to evidence-based resources and implementing SCPs.
Information technology transforming quality of cancer care in developing nations.
Authors: Rakesh Roy, Shoumini Dutta
Journal: Journal of Clinical Oncology (2012)

313 Background: Quality of cancer care is not uniform across developing nations because of poor economy, poor accessibility, illiteracy, lack of technology, etc. However Information technology (IT) has bridged the gap in recent times. Methods: Case files of patients of either sex suffering from non-small cell lung cancer of any stage. Age 35 years and above. Aim is to see impact of IT in quality of care. The following criteria were selected: Staging; Histological subtype categorization; Trucut biopsy; Search for EGFR mutations; Tailormade chemotherapy; Introduction of Palliative Care early in diagnosis. Contribution of IT for the medical team: Accessibility to standard guidelines online – NCCN, ASCO, ESMO, NICE. Using online AJCC guidelines for accurate staging. Accessing e-journals, mobile applications, online search engines. Email alerts from organisations. Systematic reviews from databases like COCHRANE. Web-based tutorials. Online mock examinations. Survival data from clinical trials. Contribution of IT for hospital administration: Computerized database of phase II and P– storing patient information. Results: Data collected in two different phases. (a) 1/1/2008– 31/12/2008. (b) 1/1/2011- 31/12/2011. Staging: complete correct staging 88% 1st phase compared to 95% in 2nd. 38% of the phase I patients could not be divided into adenocarcinoma or squamous variety whereas in 2nd group categorization could not be done in 13% of the cases. The proportion of trucut biopsy rose from 6% in phase I to 45% in phase II. Search for EGFR mutations was less than 2% in phase I vs 37% in 2nd phase. Tailormade chemotherapy – tyrosine kinase inhibitors were used as third line agents in almost all cases of phase I, but in the 2nd group 21% of patients received this agent earlier. Introduction of palliative care early in diagnosis was 3% in phase I compared to 12% in the 2nd group. Conclusions: IT support immensely changed the quality of cancer care in our institution and the standard was close to what is practiced in developed nations. Overall IT industry promoted evidence based cancer care in our institute.
RARE-44. ONE YEAR WITH OPTUNE® IN ROUTINE USE: FIRST REPORT ON CLINICAL EXPERIENCES IN GERMANY
Authors: Martin Misch, Julia Onken
Journal: Neuro-Oncology (2016)

Tumor Treating Fields (TTFields) are low intensity, intermediate frequency alternating electric fields. TTFields are delivered through 4 transducer arrays that are placed directly on the scalp to target the tumor. The delivery System is called Optune. Optune is an established, non-invasive anti mitotic therapy for the treatment of patients with newly diagnosed or recurrent glioblastoma multiforme (GBM). This is the first report on clinical experiences with Optune in Germany (N=30 patients). All patients received a prescription in the Charité Berlin, one of over 60 certified Optune-centers in Germany. We treated newly diagnosed (N=17) and recurrent GBM patients (N=13). Our patient population includes female (N=11) and male (N=19) patients in an average age of 47.9 years (25-70 years) at the prescription date. With regards to the side effects we were faced with mild to moderate skin irritation in a few patients, but those were easily handled by the use of local steroid crème and didn’t cause significant treatment breaks. Patients’ feedback showed, that none of our patients experienced a loss of quality of life. We noticed that some patients need approximately 4 weeks to get used to the therapy. Whenever patients passed those four weeks they stayed on therapy as long as possible (patients outcomes are still under evaluation). We perform regular follow-up visits for a discussion about the patient compliance that we also evaluated in our patient population. With regards to the compliance rate and due to the patient’s feedback we were able to show that patients accept this new therapy approach, if the physician explains the patient honestly what to expect: This includes an enlightenment about the significant overall survival benefit, that was shown in the Interim analysis of the EF-14 study as well as a clarification about the weight (1.3 kg) of the device.
RARE-21. A NATIONAL CANCER DATABASE ANALYSIS OF THE IMPACT OF RACE AND INSURANCE STATUS ON RECEIPT OF OBSERVATION FOR ACOUSTIC NEUROMA
Authors: Shearwood McClelland, James D Murphy, Charles R Thomas
Journal: Neuro-Oncology (2016)

Although there have been natural history studies on acoustic neuroma (AN) (Strasnick et al., 1994; Rosenberg 2000), there has been no nationwide examination of the impact of race and insurance status on the receipt of observation for AN. The National Cancer Data Base (NCDB) from 2004-2013 was used to identify patients who received observation as solitary AN treatment. A multivariable logistic regression model identified characteristics of patients who received observation, adjusting for patient age, sex, income, comorbidities, and tumor size. A total of 399 AN patients received observation as solitary treatment. Patients who were at least age 65 (OR=2.2;95%CI=1.7-2.7;p<0.0001), African-American (OR=1.5;95%CI=1.1-2.0;p=0.01), on Medicare (OR=1.8;95%CI=1.4-2.3;p=0.0003), or treated in a community hospital (OR=3.0;95%CI=1.6-5.6;p=0.0007) were more likely to receive observation. Patients on Medicaid (OR=0.8;95%CI=0.5-1.2;p=0.04) with a Charlson/Deyo score of one (OR=0.6;95%CI=0.4-0.7;p=0.003), treated in an integrated network (OR=0.8;95%CI=0.6-1.1;p<0.0001), or residing in the central United States (OR=0.6;95%CI=0.5-0.7;p=0.003) were less likely to receive observation. AN patients on Medicaid, treated in an integrated network, residing in the central United States, or with a Charlson/Deyo score of one were less likely to be treated solely with observation. Conversely elderly patients (by 120%), African-Americans (by 50%), patients on Medicare (by 80%), or patients treated in a community hospital (by 200%), were more likely to be treated solely with observation for AN. Given that African-American race and lack of private insurance are independent risk factors for in-hospital morbidity/mortality following AN surgery (Curry et al., 2010), the finding from the present analysis of African-Americans and Medicare patients being triaged to nonoperative care appears to be beneficial, while the triaging of Medicaid patients away from observation may be deleterious. Analysis of postoperative mortality following hospital discharge will be necessary to more definitively address this issue.
Value in the Step 2 Clinical Skills Examination
Authors: Donald A. Barr
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Allergen Capture by DCs during epicutaneous immunotherapy is Enhanced by Modulating the Dose and the Surface Area of the Patch
Authors: Sophie Wavrin, Lucie Mondoulet, Vincent Dioszeghy, Emilie Puteaux, Melanie Ligouis, Véronique Dhelft, Camille Plaquet, Christophe M. Dupont, Pierre-Henri Benhamou, Hugh A. Sampson
Journal: Journal of Allergy and Clinical Immunology (2017)
Performance Characteristics of the Acq-6 in Predicting Poorly Controlled Asthma in African American Teens
Authors: Michelle L. Hernandez, Allison Burbank, Krista Todoric, Carole Robinette, David Diaz-Sanchez, Robert Devlin, David B. Peden, Shannon Grabich
Journal: Journal of Allergy and Clinical Immunology (2017)
413P Sensitization of melanoma cells to nitrosourea treatment by ROS-inducing IKKβ inhibitor
Authors: A.K.-W. Tse, Y.J. Chen, X.Q. Fu, T. Su, T. Li, H. Guo, P.L. Zhu, H.Y. Kwan, B.C.Y. Cheng, H.H. Cao, S.K.W. Lee, W.F. Fong, Z.L. Yu
Journal: Annals of Oncology (2016)
Toward therapeutic drug monitoring of everolimus? Results of an exploratory study of the dose-exposure relationships
Authors: S. Falkowski, M. Deppenweiler, C. Monchaud, F. Saint-Marcoux, M.-L. Laroche, N. Picard, L. Venat-Bouvet, N. Tubiana-Mathieu, P. Marquet, J.-B. Woillard
Journal: Annals of Oncology (2016)
Chemotherapy with Granulocyte Colony Stimulating Factor (G-CSF) Alone Versus Granulocyte Colony Stimulating Factor (G-CSF) Plus Granulocyte-Macrophage Stimulating Factor (GM-CSF) for Hematopoietic Progenitor Cell Mobilization in Patients with Relapsed Non-Hodgkin’s Lymphomas (NHLs).
Authors: Chitra Hosing, Mark Munsell, Uday Popat, Martin Körbling, Rosamar Valverde, Farzaneh Maadani, Partow Kebriaei, Amin Alousi, Marcos DeLima, John McMannis, Elizabeth J. Shpall, Muzaffar H. Qazilbash, Paolo Anderlini, Sergio Giralt, Richard Champlin, Issa Khouri
Journal: Blood (2007)
Adjusted indirect comparison using propensity score matching of osimertinib to doublet chemotherapy in patients with EGFRm T790M NSCLC who have progressed after EGFR-TKI
Authors: F. Andersohn, H. Mann, T. Mitsudomi, T.S.K. Mok, J. Chih-Hsin Yang, K. Papadakis, C. Hoyle
Journal: Annals of Oncology (2016)
The chemosensitizing properties of iniparib in combination with gemcitabine (G) and carboplatin (C) in OVCAR-3 ovarian adenocarcinoma.
Authors: V. Ossovskaya, C. Lim, G. Schools, S. Kalurupalle, E. Broude, I. B. Roninson
Journal: Journal of Clinical Oncology (2011)

e15532 Background: Iniparib, a novel agent with PARP inhibitory activity, has demonstrated anticancer activity when combined with DNA-damaging chemotherapy in clinical and preclinical settings. The objective of this study was to evaluate the activity of iniparib in combination with G and C in ovarian adenocarcinoma. Methods: The chemosensitizing properties of a single dose of iniparib were evaluated in combination with G and C against OVCAR-3 ovarian adenocarcinoma 72 hours after treatment.Cell proliferation was evaluated with FACS-based cell cycle analysis, including DNA staining and bromodeoxyuridine (BrdU) incorporation. Apoptotic cells were quantified by TUNEL staining. Results: FACS analysis showed that iniparib potentiated apoptosis induced by G or C in OVCAR-3 cells (Table). Combination of iniparib with G+C enhanced apoptosis and induced S-phase cell cycle arrest in OVCAR-3 cells. Conclusions: These data demonstrate the potentiation of the antiproliferative and pro-apoptotic activities of C and G by iniparib in OVCAR-3 cells. They support the clinical investigation of iniparib in combination with these DNA-damaging agents. Treatment Sub-G1* G1* BrdU(-) S* S* G2/M* TUNEL(+) Vehicle (control) 3.42 48.34 2.85 31.11 14.29 5.5 Iniparib (0 uM) + C (0 uM) +G (0 nM) 3.42 48.24 2.70 31.43 14.21 5.5 +G (1 nM) 4.28 43.38 2.85 38.70 10.79 7.4 +G (2 nM) 6.47 27.81 3.24 54.80 7.68 9.2 Iniparib (0 uM) + C (5 uM) +G (0 nM) 11.87 15.07 6.30 34.37 32.40 14.3 +G (1 nM) 9.47 13.48 5.66 39.20 32.20 13.1 +G (2 nM) 9.11 11.26 5.53 40.12 33.98 12.0 Iniparib (0 uM) + C (10 uM) +G (0 nM) 17.06 16.55 9.35 31.45 25.59 14.8 +G (1 nM) 16.44 16.86 12.41 32.26 22.03 17.7 +G (2 nM) 20.43 21.98 11.46 26.73 19.40 18.8 Iniparib (50 uM) + C (0 uM) +G (0 nM) 4.75 42.31 4.23 32.30 16.41 14.2 +G (1 nM) 5.51 32.96 4.59 44.18 12.76 17.2 +G (2 nM) 7.84 21.38 5.09 54.58 11.10 25.1 Iniparib (50 uM) + C (5 uM) +G (0 nM) 11.07 13.52 11.37 30.02 34.02 39.2 +G (1 nM) 11.78 14.34 12.70 34.94 26.23 41.0 +G (2 nM) 11.09 13.76 10.68 36.76 27.72 42.5 Iniparib (50 uM) + C (10 uM) +G (0 nM) 14.01 16.16 14.52 30.67 24.64 49.5 +G (1 nM) 15.87 19.94 17.90 28.59 17.70 53.3 +G (2 nM) 12.60 17.99 14.43 34.04 20.93 50.3 * Data represent % cells from total population of viable cells.
IL10 and IL10:IL6 Ratio in CSF Is Useful at Diagnosis but Also in the Assessment of Therapeutic Response in Patients with Primary Central Nervous System Lymphoma (PCNSL)
Authors: Ludovic Nguyen, Myrto Costopoulos, Marie-Laure Tanguy, Caroline Houillier, Sylvain Choquet, Hind Bennani, Rwaida Elias, Marine Armand, Khe Hoang-Xuan, Sylvie Glaisner, Sandra Malak, Jacques Vargaftig, Geraldine Faivre, Frederic Davi, Helene Merle Beral, Magali Le Garff-Tavernier, Carole Soussain
Journal: Blood (2014)
OS6.6 CEVOREM Trial: Combination of EVerolimus and Octreotide in REsistant MeningiomasPresentation and Preliminary results
Authors: T. Graillon, M. Peyre, M. Kalamarides, M. Sanson, M. Barrié, C. Campello, E. Tabouret, P. Roche, H. Dufour, O. Chinot
Journal: Neuro-Oncology (2016)
Frequency of Anti-Erythropoietin Antibodies in Patients with End Stage Renal Disease Treated with Recombinant Erythropoietin.
Authors: D. Hoppensteadt, M. Tobu, D. Fareed, O. Iqbal, F. Baltasar, C. Patel, V. Bansal, M. Demir, J. Fareed
Journal: Blood (2005)
Pegfilgrastim Versus Filgrastim To Accelerate Hematopoietic Recovery after High Dose Melphalan and Autologous Hematopoietic Stem Cell Transplant (ASCT) for Multiple Myeloma.
Authors: Rebecca L. Olin, Selina M. Luger, David L. Porter, Stephen J. Schuster, Donald Tsai, Sunita Nasta, Alexander Perl, Alison W. Loren, Steven Goldstein, Patricia Mangan, Vicki Sherry, Kathleen Cunningham, Bob Sachs, Kim Hummel, Edward A. Stadtmauer
Journal: Blood (2004)
Revisiting the Heparin Nomogram: Leveraging Technology to Improve Quality
Authors: Aaron C Hamilton, John R. Bartholomew, Michael Militello, Robert Patrick, Saurabh Kandpal, Alina Bulgar, Sarah Bixler, Deborah Klein, Catherine Skowronsky, Ina Li, Keith Rosenbaum, Erron Gomez, Jennifer Goodman, Sandra Sakenes, Kandice Marchant, Shannon Phillips
Journal: Blood (2012)